Tamtam Try Tamtam free
Omnicell logo

Omnicell account plan

Healthcare technology solutions

At a glance

Omnicell is a US medication management automation company for hospitals and pharmacies, with $1,184.8 million of revenue in 2025.

Omnicell (NASDAQ: OMCL), headquartered in Fort Worth, Texas, sells medication dispensing automation, robotics, consumables, software and services to hospitals, health systems and outpatient, institutional and retail pharmacies. It reports one segment and targets the Autonomous Pharmacy, a vision of zero-error medication management, through its Titan XT cabinets and the cloud-native OmniSphere platform. In 2025 total revenues were $1,184.8 million (+7%), net income $2.1 million and ARR $636 million; about 90% of revenue came from the United States. It had about 3,580 employees at the end of 2025 and about 3,450 at September 30, 2026.

Business units

Strategic priorities

Titan XT refresh cycle
First Titan XT shipments were days away on October 29, 2026; management estimates the total replacement opportunity in excess of $2.5 billion on the installed base, hardware only.
OmniSphere cloud platform
OmniSphere is the cloud-native layer unifying devices, data and workflows; general availability for ADS is targeted for the first half of 2027, with subscription pricing still being tested.
Competitive conversions
Omnicell is pursuing customers of its primary competitor, using leasing on competitive deals; its first competitive Titan XT conversion came in Q2 2026.
EBITDA growing faster than revenue
Leadership is ring-fencing refresh-cycle investment and cutting G&A and support costs; full-year 2026 non-GAAP EBITDA guidance was raised to $187-193 million.
Outpatient pharmacy growth
Specialty Pharmacy Services and 340B solutions are the growth engine of SaaS and Expert Services, with new wins including a federally qualified health center.

Latest results

In Q3 2026 total revenues were $307.9 million, down 1%, with product revenues of $173.1 million (-3%) on lower XTExtend volumes and service revenues of $134.8 million. Gross margin rose to 45% from 43% and net income to $11.0 million ($0.24 per diluted share) from $5.5 million. For the nine months revenues were $929.9 million (+7%) and net income $46.7 million, helped by a $14.0 million IEEPA tariff refund in Q2 2026. Guidance for full-year 2026 is revenue of $1.225-1.231 billion, ARR of $660-670 million, product bookings of $425-560 million and non-GAAP EBITDA of $187-193 million.

Investments and deals

Capex and software development
Capital expenditures were $40.4 million in 2025 plus $17.5 million of external-use software development; for the first nine months of 2026, capex was $32.7 million plus $8.8 million.
Share repurchases and debt
Omnicell repurchased about 2,523,000 shares for $77.6 million in 2025 and repaid $175.0 million of convertible notes in September 2025; no repurchases were made in 2026.
Restructuring and portfolio focus
Restructurings covered EnlivenHealth, Professional Services, the product organization, the Medimat line wind-down and the exit of the Beijing, China office; 2025 restructuring expense was $6.5 million.
Acquisitions
There were no material acquisitions in 2024 or 2025; the company expects to keep seeking acquisitions of businesses, technologies or products.

Challenges and risks

Bookings timing
Sales cycles can exceed 12 to 24 months, and the low end of the bookings range reflects uncertainty around timing of purchasing decisions; the Titan XT announcement may also influence timing.
Memory chip costs
Management estimated about $6 million of incremental memory cost in the second half of 2026, expected to persist for the foreseeable future.
Tariffs
Section 301 tariffs replaced earlier tariffs, and possible Section 232 tariffs on medical equipment remain a risk; Omnicell mitigates through dual-sourcing and nearshoring.
340B and government payments
340B changes had a modest impact on 2026 ARR, and customers are preparing for lower government payments, including an expected $910 billion Medicaid spending reduction.
Competition
Rivals with greater resources and larger installed bases launched new platforms in the same refresh cycle, and EnlivenHealth faces retail pharmacy industry dynamics.

What leadership says

“Customers are validating the potential value of combining Titan XT with OmniSphere, our cloud-native platform”

Randall A. Lipps, Chairman, CEO and Founder · Q3 2026 results press release, October 29, 2026

“Leasing has become a meaningful part of our go-to-market approach on competitive deals”

Randall A. Lipps, Chairman, CEO and Founder · Q3 2026 earnings call, October 29, 2026

“Reliable hardware and OmniSphere are not separable in our view.”

Nnamdi Njoku, President and COO · Q3 2026 earnings call, October 29, 2026

“Our EBITDA is growing meaningfully faster than revenue this year, even as top line growth remains modest”

Baird Radford, EVP and CFO · Q3 2026 earnings call, October 29, 2026

Where a supplier can help

Semiconductor and component supply
Tied to the memory chip cost and tariff challenges: alternative memory and component sources, and nearshored contract manufacturing, support the dual-sourcing strategy.
Cloud infrastructure and security
Tied to the OmniSphere priority: cloud hosting, migration and healthcare security services help move customers from on-premise to cloud by the 2027 general availability.
Installation and field capacity
Tied to the Titan XT refresh cycle: installation, logistics and field service partners help deploy hardware across a large installed base and in waves on large deals.
Lease financing partners
Tied to the competitive conversions priority: finance companies can buy lease receivables, which Omnicell already sells to third parties, as leasing grows on competitive deals.
Cost efficiency in G&A
Tied to the EBITDA priority: tools that automate support functions fit leadership's cuts outside innovation and go-to-market.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Omnicell?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Omnicell

What does Omnicell do?

Omnicell sells medication dispensing automation, central pharmacy robotics, packaging consumables, software and services to hospitals and pharmacies, aiming at autonomous, zero-error medication management.

What is Omnicell's revenue?

Total revenues were $1,184.8 million in 2025 (+7%). For 2026 the company guides revenue of $1.225-1.231 billion.

How many employees does Omnicell have?

About 3,580 at December 31, 2025 and about 3,450 full-time at September 30, 2026.

What is Omnicell's strategy?

It is driving a refresh of its installed base to Titan XT cabinets combined with the cloud-native OmniSphere platform, pursuing competitive conversions with leasing, and growing Specialty Pharmacy and 340B services.

Who leads Omnicell?

Randall A. Lipps is Chairman, CEO and Founder; Nnamdi Njoku is President and COO; Baird Radford is EVP and CFO.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)